ArticleSurgery today2026
Good Responders to Rectal Cancer Neoadjuvant Chemotherapy, based on the MRI Findings Can Help to Avoid Radiotherapy: A Comparative Analysis.
Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo identify the prognostic factors in preoperatively treated rectal cancer and select patients who could be treated with neoadjuvant chemotherapy (NAC) alone.
methodsA total of 78 patients, 58 in the NAC group and 20 in the radiation therapy (RT) group, with rectal cancer deeper than cT3 or N+ were studied from 2016 to 2022. The survival outcomes after neoadjuvant therapy and poor prognostic factors were analyzed.
resultsThe median follow-up period was 63 months in the NAC group and 52 months in the RT group. In the multivariate analyses of all patients, a posttreatment mesorectal fascia (MRF)-positive status yielded a poor prognosis for the disease-free survival (HR, 5.051; 95% CI; 1.198-21.30, P = 0.027) and local recurrence (HR, 9.937; 95% CI; 1.282-77.05, P = 0.028). In posttreatment MRF-negative cases, the 3-year disease-free survival was 85.7% in both the NAC and RT groups (P = 0.950). The 3-year local recurrence rate was 14.3% in the RT group and 0% in the NAC group (P = 0.173).
conclusionsPosttreatment MRF positivity is an independent risk factor for a poor disease-free survival and local recurrence. However, posttreatment MRF negative cases that respond to NAC have comparable survival outcomes to those who undergo RT.
Indexed as
Identifiers
42240882What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.